Xiaolan Bian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaolan Bian has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Jie Fang
Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
6 shared publicationsXiaoshuang He
Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
4 shared publicationsHui Li
Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
3 shared publicationsPing Yu
Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pharm, Sch Med, Shanghai, Peoples R China
3 shared publications- Qiuya Lu
Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
3 shared publications Xuan He
Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pharm, Sch Med, Shanghai, Peoples R China
3 shared publications
Latest Publications
- Open Access
- 19 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1625697
Unexpected renal influence on isavuconazole trough concentrations: two case reports and literature review
Isavuconazole (ISA) is a first-line treatment for invasive aspergillosis, with routine therapeutic drug monitoring (TDM) typically deemed unnecessary. Although the drug label and prior studies suggest renal function does not affect ISA pharmacokinetics, our findings in two high-risk patients challenge this perspective, showing an inverse correlation between ISA trough concentrations and estimated glomerular filtration rate (eGFR). Trough concentrations exceeding the reported toxicity threshold were associated with adverse drug reactions (ADRs). Given the limited sample size, large-scale retrospective and prospective studies are urgently needed to confirm the impact of renal function on ISA and to develop individualized TDM strategies that optimize efficacy and minimize toxicity.
- 19 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1625697
Open AccessUnexpected renal influence on isavuconazole trough concentrations: two case reports and literature review
Isavuconazole (ISA) is a first-line treatment for invasive aspergillosis, with routine therapeutic drug monitoring (TDM) typically deemed unnecessary. Although the drug label and prior studies suggest renal function does not affect ISA pharmacokinetics, our findings in two high-risk patients challenge this perspective, showing an inverse correlation between ISA trough concentrations and estimated glomerular filtration rate (eGFR). Trough concentrations exceeding the reported toxicity threshold were associated with adverse drug reactions (ADRs). Given the limited sample size, large-scale retrospective and prospective studies are urgently needed to confirm the impact of renal function on ISA and to develop individualized TDM strategies that optimize efficacy and minimize toxicity.
- 15 August 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 266, 117117
Antibody-free quantification of serum infliximab using LC-MS/MS
- 15 August 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 266, 117117
Antibody-free quantification of serum infliximab using LC-MS/MS
- Open Access
- 17 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (12) , e040698
Association of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics and Hemorrhage Risk Factors in Patients With Venous Thromboembolism
Background: Rivaroxaban is a first‐line agent for venous thromboembolism prophylaxis and treatment. However, its pharmacokinetics, pharmacodynamics, and bleeding risk exhibit significant interindividual variability. Known nongenetic factors alone cannot fully explain this variability, and the impact of genetic polymorphisms remains debated. Methods: From December 29, 2021, to May 11, 2023, 310 patients with venous thromboembolism treated with rivaroxaban were enrolled in this observational study from a tertiary hospital in Shanghai, China, based on predefined criteria. We assessed relationships between rivaroxaban concentrations, anti‐Factor Xa levels, and coagulation parameters; examined the impact of 12 genes on concentrations and anti‐Factor Xa levels; and followed up for at least 3 months to identify bleeding risk factors. Results: Rivaroxaban plasma concentration was significantly related to anti‐Factor Xa levels (R 2 =0.697), activated partial thromboplastin time (R 2 =0.134), prothrombin time (R 2 =0.123), and international normalized ratio (R 2 =0.116). Peak concentrations were associated with cytochrome p450 3A5 (rs776746, P =0.023), sushi domain‐containing protein 3 ( rs76292544, P =0.034), and ATP‐binding cassette subfamily G member 2 ( rs1045642, P =0.012); trough concentrations were linked to cytochrome p450 3A5 (rs776746, P =0.045), sushi domain‐containing protein 3 (rs76292544, P =0.014), and ATP‐binding cassette subfamily G member 2 (rs2231142, P =0.029); peak anti‐Factor Xa levels were associated with aldo‐keto reductase family 7 member A3 (rs1738023, P =0.022; rs1738025, P =0.035) and ATP‐binding cassette subfamily A member 6 (rs7212506, P =0.044). However, these genetic associations were not significant after Bonferroni correction. Hemorrhage risk factors were anemia, pulmonary embolism, and the TT genotype of sushi domain‐containing protein 3 (rs76292544). Conclusions: Pharmacogenetic monitoring and hemorrhage risk assessment may contribute to optimize its efficacy and safety. Larger‐scale, global multicenter clinical trials are required to validate the potential gene loci for testing, including cytochrome p450 3A5 (rs776746), sushi domain‐containing protein 3 (rs76292544), ATP‐binding cassette transporter B1 (rs1045642), and ATP‐binding cassette subfamily G member 2 (rs2231124), with particular focus on sushi domain‐containing protein 3 (rs76292544).
- 17 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (12) , e040698
Open AccessAssociation of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics and Hemorrhage Risk Factors in Patients With Venous Thromboembolism
Background: Rivaroxaban is a first‐line agent for venous thromboembolism prophylaxis and treatment. However, its pharmacokinetics, pharmacodynamics, and bleeding risk exhibit significant interindividual variability. Known nongenetic factors alone cannot fully explain this variability, and the impact of genetic polymorphisms remains debated. Methods: From December 29, 2021, to May 11, 2023, 310 patients with venous thromboembolism treated with rivaroxaban were enrolled in this observational study from a tertiary hospital in Shanghai, China, based on predefined criteria. We assessed relationships between rivaroxaban concentrations, anti‐Factor Xa levels, and coagulation parameters; examined the impact of 12 genes on concentrations and anti‐Factor Xa levels; and followed up for at least 3 months to identify bleeding risk factors. Results: Rivaroxaban plasma concentration was significantly related to anti‐Factor Xa levels (R 2 =0.697), activated partial thromboplastin time (R 2 =0.134), prothrombin time (R 2 =0.123), and international normalized ratio (R 2 =0.116). Peak concentrations were associated with cytochrome p450 3A5 (rs776746, P =0.023), sushi domain‐containing protein 3 ( rs76292544, P =0.034), and ATP‐binding cassette subfamily G member 2 ( rs1045642, P =0.012); trough concentrations were linked to cytochrome p450 3A5 (rs776746, P =0.045), sushi domain‐containing protein 3 (rs76292544, P =0.014), and ATP‐binding cassette subfamily G member 2 (rs2231142, P =0.029); peak anti‐Factor Xa levels were associated with aldo‐keto reductase family 7 member A3 (rs1738023, P =0.022; rs1738025, P =0.035) and ATP‐binding cassette subfamily A member 6 (rs7212506, P =0.044). However, these genetic associations were not significant after Bonferroni correction. Hemorrhage risk factors were anemia, pulmonary embolism, and the TT genotype of sushi domain‐containing protein 3 (rs76292544). Conclusions: Pharmacogenetic monitoring and hemorrhage risk assessment may contribute to optimize its efficacy and safety. Larger‐scale, global multicenter clinical trials are required to validate the potential gene loci for testing, including cytochrome p450 3A5 (rs776746), sushi domain‐containing protein 3 (rs76292544), ATP‐binding cassette transporter B1 (rs1045642), and ATP‐binding cassette subfamily G member 2 (rs2231124), with particular focus on sushi domain‐containing protein 3 (rs76292544).
- 27 May 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1002, 177776
Towards zebrafish model applications in drug discovery targeting central nervous system diseases and neurotoxicity assessment
- 27 May 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1002, 177776
Towards zebrafish model applications in drug discovery targeting central nervous system diseases and neurotoxicity assessment
- 31 May 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (3) , 107232
Risk factor analysis for the occurrence of colistin-related nephrotoxicity: A retrospective observational cohort study
- 31 May 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (3) , 107232
Risk factor analysis for the occurrence of colistin-related nephrotoxicity: A retrospective observational cohort study
- Open Access
- 1 December 2023
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 15 (12) , 6687-6696
Risk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study
Background: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a common immune-related adverse event (irAE) related to camrelizumab. This study aimed to investigate the risk factors of RCCEP and its association with patients’ survival. Methods: This retrospective study collected the data of consecutive patients with non-small cell lung cancer (NSCLC) who received camrelizumab between January 2019 and December 2021. Baseline characteristics and peripheral blood biomarkers were collected. The outcomes were the occurrence of RCCEP and progression-free survival (PFS). The factors associated with RCCEP were analyzed using univariable and multivariable logistic regression. The association between PFS and RCCEP occurrence was analyzed by the log-rank test. Results: Among the 80 patients included, 24 (30.0%) developed RCCEP, and 56 did not. Among the patients with RCCEP, only four reported the occurrence of grade 3–4 RCCEP. The multivariable analysis revealed that a percentage of eosinophil (EOS%) >1.75% was significantly associated with a higher risk of RCCEP [odds ratio (OR) =4.484; 95% confidence interval (CI): 1.139–17.651] and camrelizumab combined with an anti-angiogenic agent was significantly associated with a lower risk of RCCEP (OR =0.188; 95% CI: 0.055–0.639). The median PFS was numerically longer in patients with RCCEP than in those who did not (17 vs. 9 months, P=0.069). Patients who had baseline EOS% >1.75% and received camrelizumab without an anti-angiogenic agent had a longer median PFS than those who did not (17 vs. 9 months, P=0.011). Conclusions: Baseline EOS% >1.75% and camrelizumab without an anti-angiogenic agent were risk factors of RCCEP and might be associated with better survival in patients with NSCLC.
- 1 December 2023
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 15 (12) , 6687-6696
Open AccessRisk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study
Background: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a common immune-related adverse event (irAE) related to camrelizumab. This study aimed to investigate the risk factors of RCCEP and its association with patients’ survival. Methods: This retrospective study collected the data of consecutive patients with non-small cell lung cancer (NSCLC) who received camrelizumab between January 2019 and December 2021. Baseline characteristics and peripheral blood biomarkers were collected. The outcomes were the occurrence of RCCEP and progression-free survival (PFS). The factors associated with RCCEP were analyzed using univariable and multivariable logistic regression. The association between PFS and RCCEP occurrence was analyzed by the log-rank test. Results: Among the 80 patients included, 24 (30.0%) developed RCCEP, and 56 did not. Among the patients with RCCEP, only four reported the occurrence of grade 3–4 RCCEP. The multivariable analysis revealed that a percentage of eosinophil (EOS%) >1.75% was significantly associated with a higher risk of RCCEP [odds ratio (OR) =4.484; 95% confidence interval (CI): 1.139–17.651] and camrelizumab combined with an anti-angiogenic agent was significantly associated with a lower risk of RCCEP (OR =0.188; 95% CI: 0.055–0.639). The median PFS was numerically longer in patients with RCCEP than in those who did not (17 vs. 9 months, P=0.069). Patients who had baseline EOS% >1.75% and received camrelizumab without an anti-angiogenic agent had a longer median PFS than those who did not (17 vs. 9 months, P=0.011). Conclusions: Baseline EOS% >1.75% and camrelizumab without an anti-angiogenic agent were risk factors of RCCEP and might be associated with better survival in patients with NSCLC.
- 18 November 2023
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 30 (6) , 561-572
Sacubitril/Valsartan in Heart Failure with Hypertension Patients: Real-World Experiences on Different Ages, Drug Doses, and Renal Functions
Introduction Hypertension is a significant risk factor in heart failure for worldwide patients. More than half of hypertensive patients suffer from heart failure. Recently, sacubitril/valsartan (sac/val) has been approved as an antihypertensive agent in China and Japan. Additionally, it is not approved for treating hypertension in Europe or the USA. Aim To accumulate more real-world experiences to investigate the effectiveness and optimize clinical medication of sac/val in hypertensive patients with heart failure. Methods We retrospectively enrolled adult patients diagnosed with hypertension (HTN) and heart failure (HF) and newly treated with sac/val. The baseline characteristics and clinical outcomes were retrospectively extracted from electronic medical records (EMR) in three centers. The efficacy and safety of sac/val were first analyzed in all enrolled patients. Stratified analyses were conducted in patients with different ages (≥ 65, < 65), maximum tolerated doses (≥ 200 mg/days, < 200 mg/days), and renal functions (e-GFR ≥ 60 ml/min/1.73 m2, < 60 ml/min/1.73 m2). Results Overall, 794 patients diagnosed with both HF and HTN were included in our study. During follow-up, significant reductions were found in blood pressure (BP) (SBP 12.8 ± 21.2 mmHg, P < 0.001, DBP 7.1 ± 16.5 mmHg, P < 0.001), and cardiac biomarkers (cardiac troponin 1.78 ± 19.1 ng/mL, P < 0.001, NT-proBNP 1403 ± 6937 pg/mL, P < 0.001) from baseline. In stratification analyses, the lower dosage group earned a higher BP control rate (83.4% vs. 75.6%, P = 0.025) and an overall improvement rate of cardiac indicators (61.3% vs. 48.0%, P = 0.002). The younger patients’ group had significantly less cumulative hazard of recurrent cerebral-cardiovascular events than the elder group (log-rank P value < 0.001). Patients with renal dysfunction were observed with more AE incidences. Conclusions Sac/val could reduce BP and improve cardiac structural and functional parameters in hypertensive patients with HF, even with less than target doses. However, more attention should be paid to older patients and renal dysfunction patients when using sac/val because of additional risks in adverse events.
- 18 November 2023
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 30 (6) , 561-572
Sacubitril/Valsartan in Heart Failure with Hypertension Patients: Real-World Experiences on Different Ages, Drug Doses, and Renal Functions
Introduction Hypertension is a significant risk factor in heart failure for worldwide patients. More than half of hypertensive patients suffer from heart failure. Recently, sacubitril/valsartan (sac/val) has been approved as an antihypertensive agent in China and Japan. Additionally, it is not approved for treating hypertension in Europe or the USA. Aim To accumulate more real-world experiences to investigate the effectiveness and optimize clinical medication of sac/val in hypertensive patients with heart failure. Methods We retrospectively enrolled adult patients diagnosed with hypertension (HTN) and heart failure (HF) and newly treated with sac/val. The baseline characteristics and clinical outcomes were retrospectively extracted from electronic medical records (EMR) in three centers. The efficacy and safety of sac/val were first analyzed in all enrolled patients. Stratified analyses were conducted in patients with different ages (≥ 65, < 65), maximum tolerated doses (≥ 200 mg/days, < 200 mg/days), and renal functions (e-GFR ≥ 60 ml/min/1.73 m2, < 60 ml/min/1.73 m2). Results Overall, 794 patients diagnosed with both HF and HTN were included in our study. During follow-up, significant reductions were found in blood pressure (BP) (SBP 12.8 ± 21.2 mmHg, P < 0.001, DBP 7.1 ± 16.5 mmHg, P < 0.001), and cardiac biomarkers (cardiac troponin 1.78 ± 19.1 ng/mL, P < 0.001, NT-proBNP 1403 ± 6937 pg/mL, P < 0.001) from baseline. In stratification analyses, the lower dosage group earned a higher BP control rate (83.4% vs. 75.6%, P = 0.025) and an overall improvement rate of cardiac indicators (61.3% vs. 48.0%, P = 0.002). The younger patients’ group had significantly less cumulative hazard of recurrent cerebral-cardiovascular events than the elder group (log-rank P value < 0.001). Patients with renal dysfunction were observed with more AE incidences. Conclusions Sac/val could reduce BP and improve cardiac structural and functional parameters in hypertensive patients with HF, even with less than target doses. However, more attention should be paid to older patients and renal dysfunction patients when using sac/val because of additional risks in adverse events.
- Open Access
- 17 August 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 11 (5) , 1917-1934
Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study
Introduction Considering the importance of ceftazidime/avibactam (CAZ/AVI) and polymyxin B (PMB) in treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infection, it is essential to evaluate the efficacy and safety of these agents and provide appropriate medical advice to clinical specialists. Methods We conducted a retrospective cohort study in two Chinese tertiary hospitals for critically ill patients with CRKP infection who received at least 24-h CAZ/AVI-based or PMB-based treatment. A binary logistic model and a Cox proportional hazards regression model were constructed to analyze variables that could potentially affect 30-day microbiological eradication and all-cause mortality, respectively. Results From January 2019 to December 2021, 164 eligible patients were divided into CAZ/AVI and PMB cohorts. A notably lower 30-day mortality rate (35.4% vs 69.5%, P < 0.001) and a higher 30-day microbiological eradication rate (80.5% vs 32.9%, P < 0.001) were observed for patients receiving CAZ/AVI-based treatment, compared with cases in the PMB group. A longer antimicrobial treatment duration (> 7 days) could also significantly decrease the mortality rate and increase the microbiological eradication rate. Female patients had a higher survival rate than male patients. Age over 65 years, sepsis, continuous renal replacement therapy, and organ transplantation were identified as negative factors for survival. In the subgroup analysis, CAZ/AVI combined with tigecycline or amikacin could effectively lower mortality. According to safety evaluation results, potential elevation of hepatic enzymes was associated with CAZ/AVI-based treatment, while renal impairment was probably related to PMB-based treatment. Conclusions CAZ/AVI was more effective than PMB in treating CRKP-infected patients. Tigecycline and amikacin were proven to be beneficial as concomitant agents in combination with CAZ/AVI. A treatment period lasting over 7 days was recommended. Hepatoxicity of CAZ/AVI and nephrotoxicity of PMB should be monitored carefully. Further well-designed studies should be performed to verify our conclusion.
- 17 August 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 11 (5) , 1917-1934
Open AccessCeftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study
Introduction Considering the importance of ceftazidime/avibactam (CAZ/AVI) and polymyxin B (PMB) in treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infection, it is essential to evaluate the efficacy and safety of these agents and provide appropriate medical advice to clinical specialists. Methods We conducted a retrospective cohort study in two Chinese tertiary hospitals for critically ill patients with CRKP infection who received at least 24-h CAZ/AVI-based or PMB-based treatment. A binary logistic model and a Cox proportional hazards regression model were constructed to analyze variables that could potentially affect 30-day microbiological eradication and all-cause mortality, respectively. Results From January 2019 to December 2021, 164 eligible patients were divided into CAZ/AVI and PMB cohorts. A notably lower 30-day mortality rate (35.4% vs 69.5%, P < 0.001) and a higher 30-day microbiological eradication rate (80.5% vs 32.9%, P < 0.001) were observed for patients receiving CAZ/AVI-based treatment, compared with cases in the PMB group. A longer antimicrobial treatment duration (> 7 days) could also significantly decrease the mortality rate and increase the microbiological eradication rate. Female patients had a higher survival rate than male patients. Age over 65 years, sepsis, continuous renal replacement therapy, and organ transplantation were identified as negative factors for survival. In the subgroup analysis, CAZ/AVI combined with tigecycline or amikacin could effectively lower mortality. According to safety evaluation results, potential elevation of hepatic enzymes was associated with CAZ/AVI-based treatment, while renal impairment was probably related to PMB-based treatment. Conclusions CAZ/AVI was more effective than PMB in treating CRKP-infected patients. Tigecycline and amikacin were proven to be beneficial as concomitant agents in combination with CAZ/AVI. A treatment period lasting over 7 days was recommended. Hepatoxicity of CAZ/AVI and nephrotoxicity of PMB should be monitored carefully. Further well-designed studies should be performed to verify our conclusion.